Interventionelle Onkologie – was der Radiologe im Tumorboard wissen sollte

Lukas Philipp Beyer; Lukas Lürken; Michael Doppler; Christian Stroszczynski

doi:10.1055/a-0851-4562

Radiologie up2date, Table of Contents

Radiologie up2date 2019; 19(03): 251-265
DOI: 10.1055/a-0851-4562

Interventionelle Radiologie

Georg Thieme Verlag KG Stuttgart · New York

Interventionelle Onkologie – was der Radiologe im Tumorboard wissen sollte

Lukas Philipp Beyer

,

Lukas Lürken

,

Michael Doppler

,

Christian Stroszczynski

Abstract

All articles of this category

In den letzten Jahren hat die interventionelle Onkologie enorme Fortschritte erzielt. Themen dieses Beitrags sind die technischen Möglichkeiten und die Grenzen der perkutanen Ablation und der Embolisation einerseits und der aktuelle Stand zum therapeutischen Vorgehen bei den wichtigsten Tumorentitäten andererseits.

Schlüsselwörter

Tumorablation - Chemoembolisation - hepatozelluläres Karzinom - kolorektales Karzinom - Lebermetastasen

Key words

tumor ablation - chemoembolization - hepatocellular carcinoma - colorectal cancer - liver metastases

Full Text

References

Literatur
1 Goldberg SN, Gazelle GS, Dawson SL. et al. Tissue ablation with radiofrequency: effect of probe size, gauge, duration, and temperature on lesion volume. Acad Radiol 1995; 2: 399-404
2 Brace CL. Radiofrequency and Microwave Ablation of the Liver, Lung, Kidney, and Bone: What Are the Differences?. Curr Probl Diagn Radiol 2009; 38: 135-143 doi:10.1067/j.cpradiol.2007.10.001
3 Harari CM, Magagna M, Bedoya M. et al. Microwave Ablation: Comparison of Simultaneous and Sequential Activation of Multiple Antennas in Liver Model Systems. Radiology 2016; 278: 95-103 doi:10.1148/radiol.2015142151
4 Lee EW, Chen C, Prieto VE. et al. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 2010; 255: 426-433 doi:10.1148/radiol.10090337
5 Cannon R, Ellis S, Hayes D. et al. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013; 107: 544-549 doi:10.1002/jso.23280
6 Kim Y, Lim HK, Rhim H. et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: Analysis of prognostic factors. J Hepatol 2013; 58: 89-97 doi:10.1016/j.jhep.2012.09.020
7 Kang TW, Rhim H, Lee MW. et al. Radiofrequency Ablation for Hepatocellular Carcinoma Abutting the Diaphragm: Comparison of Effects of Thermal Protection and Therapeutic Efficacy. Am J Roentgenol 2011; 196: 907-913 doi:10.2214/AJR.10.4584
8 Teratani T, Yoshida H, Shiina S. et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006; 43: 1101-1108 doi:10.1002/hep.21164
9 Kang TW, Lim HK, Lee MW. et al. Long-term Therapeutic Outcomes of Radiofrequency Ablation for Subcapsular versus Nonsubcapsular Hepatocellular Carcinoma: A Propensity Score Matched Study. Radiology 2016; 280: 300-312 doi:10.1148/radiol.2016151243
10 Nakagomi R, Tateishi R, Shiina S. et al. Drastically Reduced Neoplastic Seeding Related to Radiofrequency Ablation for Hepatocellular Carcinoma. Am J Gastroenterol 2014; 109: 774-776 doi:10.1038/ajg.2014.42
11 Choi D, Lim HK, Kim MJ. et al. Liver Abscess After Percutaneous Radiofrequency Ablation for Hepatocellular Carcinomas: Frequency and Risk Factors. Am J Roentgenol 2005; 184: 1860-1867 doi:10.2214/ajr.184.6.01841860
12 Venkatesan AM, Kundu S, Sacks D. et al. Society of Interventional Radiology Standards of Practice Committee. Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association [corrected]. J Vasc Interv Radiol 2010; 21: 1611-1630 doi:10.1016/j.jvir.2010.07.018 quiz 1631
13 Miyayama S, Yamashiro M, Ikuno M. et al. Ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinoma guided by automated tumor-feeders detection software: technical success and short-term tumor response. Abdom Imaging 2014; 39: 645-656 doi:10.1007/s00261-014-0094-0
14 Lammer J, Malagari K, Vogl T. et al. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. Cardiovasc Intervent Radiol 2010; 33: 41-52 doi:10.1007/s00270-009-9711-7
15 Håkansson L, Håkansson A, Morales O. et al. Spherex (degradable starch microspheres) chemo-occlusion-enhancement of tumor drug concentration and therapeutic efficacy: an overview. Semin Oncol 1997; 24: S6-100-S6-109
16 Orlacchio A, Chegai F, Francioso S. et al. Repeated Transarterial Chemoembolization with Degradable Starch Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study. Curr Med Imaging Rev 2018; 14: 637-645 doi:10.2174/1573405613666170616123657
17 Vogel A, Cervantes A, Chau I. et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;
18 Galle PR, Forner A, Llovet JM. et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236 doi:10.1016/j.jhep.2018.03.019
19 Rahbari NN, Mehrabi A, Mollberg NM. et al. Hepatocellular Carcinoma. Ann Surg 2011; 253: 453-469 doi:10.1097/SLA.0b013e31820d944f
20 Cucchetti A, Piscaglia F, Cescon M. et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59: 300-307 doi:10.1016/j.jhep.2013.04.009
21 Liu Y, Zheng Y, Li S. et al. Percutaneous microwave ablation of larger hepatocellular carcinoma. Clin Radiol 2013; 68: 21-26 doi:10.1016/j.crad.2012.05.007
22 Yang DJ, Luo KL, Liu H. et al. Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma. Oncotarget 2017; 8: 2960-2970 doi:10.18632/oncotarget.13813
23 Shibata T, Isoda H, Hirokawa Y. et al. Small Hepatocellular Carcinoma: Is Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization More Effective than Radiofrequency Ablation Alone for Treatment?. Radiology 2009; 252: 905-913 doi:10.1148/radiol.2523081676
24 Lo C, Ngan H, Tso WK. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171 doi:10.1053/jhep.2002.33156
25 Llovet JM, Real MI, Montaña X. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (London, England) 2002; 359: 1734-1739 doi:10.1016/S0140-6736(02)08649-X
26 Llovet J, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442 doi:10.1053/jhep.2003.50047
27 Burrel M, Reig M, Forner A. et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-1335 doi:10.1016/j.jhep.2012.01.008
28 Takayasu K, Arii S, Kudo M. et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56: 886-892 doi:10.1016/j.jhep.2011.10.021
29 Prajapati HJ, Kim HS. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization. PLoS One 2017; 12: e0170750 doi:10.1371/journal.pone.0170750
30 Kirstein MM, Voigtländer T, Schweitzer N. et al. Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. United Eur Gastroenterol J 2018; 6: 238-246 doi:10.1177/2050640617716597
31 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Kolorektales Karzinom, Langversion 2.1, 2019, AWMF Registrierungsnummer: 021/007OL.
32 Van Cutsem E, Cervantes A, Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-1422 doi:10.1093/annonc/mdw235
33 House MG, Ito H, Gönen M. et al. Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single Institution. J Am Coll Surg 2010; 210: 744-752 doi:10.1016/j.jamcollsurg.2009.12.040
34 Otto G, Düber C, Hoppe-Lotichius M. et al. Radiofrequency Ablation as First-Line Treatment in Patients With Early Colorectal Liver Metastases Amenable to Surgery. Ann Surg 2010; 251: 796-803 doi:10.1097/SLA.0b013e3181bc9fae
35 Solbiati L, Ahmed M, Cova L. et al. Small Liver Colorectal Metastases Treated with Percutaneous Radiofrequency Ablation: Local Response Rate and Long-term Survival with Up to 10-year Follow-up. Radiology 2012; 265: 958-968 doi:10.1148/radiol.12111851
36 Sørensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 2007; 48: 253-258 doi:10.1080/02841850601161539
37 Correa-Gallego C, Fong Y, Gonen M. et al. A Retrospective Comparison of Microwave Ablation vs. Radiofrequency Ablation for Colorectal Cancer Hepatic Metastases. Ann Surg Oncol 2014; 21: 4278-4283 doi:10.1245/s10434-014-3817-0
38 Niessen C, Thumann S, Beyer L. et al. Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep 2017; 7: 43687 doi:10.1038/srep43687
39 de Baère T, Aupérin A, Deschamps F. et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 2015; 26: 987-991 doi:10.1093/annonc/mdv037
40 Hiraki T, Gobara H, Iguchi T. et al. Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer. World J Gastroenterol 2014; 20: 988 doi:10.3748/wjg.v20.i4.988
41 Fiorentini G, Aliberti C, Tilli M. et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32: 1387-1395
42 Martin RCG, Scoggins CR, Schreeder M. et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015; 121: 3649-3658 doi:10.1002/cncr.29534
43 Bhutiani N, Akinwande O, Martin RCG. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases. World J Surg 2016; 40: 1178-1190 doi:10.1007/s00268-015-3386-9
44 Jones RP, Malik HZ, Fenwick SW. et al. PARAGON II – A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. Eur J Surg Oncol 2016; 42: 1866-1872 doi:10.1016/j.ejso.2016.07.142
45 Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166: 1611-1623
46 Crépel M, Jeldres C, Sun M. et al. A Population-based Comparison of Cancer-control Rates Between Radical and Partial Nephrectomy for T1A Renal Cell Carcinoma. Urology 2010; 76: 883-888 doi:10.1016/J.UROLOGY.2009.08.028
47 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 1.2, 2017, AWMF Registernummer: 043/017OL.
48 Ljungberg B, Albiges L, Abu-Ghanem Y. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol 2019; 75: 799-810 doi:10.1016/j.eururo.2019.02.011
49 Gordetsky J, Eich ML, Garapati M. et al. Active Surveillance of Small Renal Masses. Urology 2019; 123: 157-166 doi:10.1016/j.urology.2018.09.017
50 Xing M, Kokabi N, Zhang D. et al. Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)–Medicare-linked Population Study. Radiology 2018; 288: 81-90 doi:10.1148/radiol.2018171407
51 Atwell TD, Schmit GD, Boorjian SA. et al. Percutaneous Ablation of Renal Masses Measuring 3.0 cm and Smaller: Comparative Local Control and Complications After Radiofrequency Ablation and Cryoablation. Am J Roentgenol 2013; 200: 461-466 doi:10.2214/AJR.12.8618
52 Samarasekera D, Khalifeh A, Autorino R. et al. 1795 Percutaneous radiofrequency ablation versus percutaneous cryoablation: long-term outcomes following ablation for renal cell carcinoma. J Urol 2013; 189: e737-e738 doi:10.1016/j.juro.2013.02.2845
53 Zhou W, Arellano RS. Thermal Ablation of T1c Renal Cell Carcinoma: A Comparative Assessment of Technical Performance, Procedural Outcome, and Safety of Microwave Ablation, Radiofrequency Ablation, and Cryoablation. J Vasc Interv Radiol 2018; 29: 943-951 doi:10.1016/j.jvir.2017.12.020
54 Valle JW, Borbath I, Khan SA. et al. ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2016; 27: v28-v37 doi:10.1093/annonc/mdw324
55 Kim JH, Won HJ, Shin YM. et al. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol 2011; 80: e221-e225 doi:10.1016/j.ejrad.2010.09.019
56 Butros SR, Shenoy-Bhangle A, Mueller PR. et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome. Clin Imaging 2014; 38: 490-494 doi:10.1016/j.clinimag.2014.01.013
57 Kim JH, Won HJ, Shin YM. et al. Radiofrequency Ablation for the Treatment of Primary Intrahepatic Cholangiocarcinoma. Am J Roentgenol 2011; 196: W205-W209 doi:10.2214/AJR.10.4937
58 Park SY, Kim JH, Yoon HJ. et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 2011; 66: 322-328 doi:10.1016/j.crad.2010.11.002
59 Kiefer MV, Albert M, McNally M. et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011; 117: 1498-1505 doi:10.1002/cncr.25625
60 Hyder O, Marsh JW, Salem R. et al. Intra-arterial Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis. Ann Surg Oncol 2013; 20: 3779-3786 doi:10.1245/s10434-013-3127-y
61 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S2k-Leitlinie Neuroendokrine Tumore, 2018, AWMF Registrierungsnummer: 021/27.
62 Bloomston M, Al-Saif O, Klemanski D. et al. Hepatic Artery Chemoembolization in 122 Patients with Metastatic Carcinoid Tumor: Lessons Learned. J Gastrointest Surg 2007; 11: 264-271 doi:10.1007/s11605-007-0089-z
63 Saxena A, Chua TC, Sarkar A. et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery 2011; 149: 209-220 doi:10.1016/j.surg.2010.06.008
64 de Baere T, Deschamps F, Tselikas L. et al. GEP-NETS UPDATE: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol 2015; 172: R151-R166 doi:10.1530/EJE-14-0630
65 Apfelbeck M, Herlemann A, Stief CG. et al. Fokale Therapie des Prostatakarzinoms in Deutschland. Urologe 2016; 55: 584-592 doi:10.1007/s00120-016-0104-7
66 Valerio M, Cerantola Y, Eggener SE. et al. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol 2017; 71: 17-34 doi:10.1016/j.eururo.2016.08.044
67 van der Poel HG, van den Bergh RCN, Briers E. et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018; 74: 84-91 doi:10.1016/J.EURURO.2018.01.001
68 Senkus E, Kyriakides S, Ohno S. et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: v8-v30 doi:10.1093/annonc/mdv298
69 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1, 2018 AWMF Registernummer: 032 – 045OL.
70 Chua TC, Saxena A, Liauw W. et al. Hepatic resection for metastatic breast cancer: A systematic review. Eur J Cancer 2011; 47: 2282-2290 doi:10.1016/j.ejca.2011.06.024
71 Wang M, Zhang J, Ji S. et al. Transarterial chemoembolisation for breast cancer with liver metastasis: A systematic review. Breast 2017; 36: 25-30 doi:10.1016/j.breast.2017.09.001
72 Wolf FJ, Grand DJ, Machan JT. et al. Microwave Ablation of Lung Malignancies: Effectiveness, CT Findings, and Safety in 50 Patients. Radiology 2008; 247: 871-879 doi:10.1148/radiol.2473070996